The biogenesis, function and clinical significance of circular RNAs in breast cancer

Yan Zeng, Yutian Zou, Guanfeng Gao, Shaoquan Zheng, Song Wu, Xiaoming Xie, Hailin Tang
Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China

ABSTRACT
Circular RNAs (circRNAs) are noncoding RNAs that form covalently closed loop structures. CircRNAs are dysregulated in cancer and play key roles in tumorigenesis, diagnosis, and tumor therapy. CircRNAs function as competing endogenous RNAs or microRNA sponges that regulate transcription and splicing, binding to proteins, and translation. CircRNAs may serve as novel biomarkers for cancer diagnosis, and they show potential as therapeutic targets in cancers including breast cancer (BC). In women, BC is the most common malignant tumor worldwide and the second leading cause of cancer death. Although evidence indicates that circRNAs play a critical role in BC, the mechanisms regulating the function of circRNAs in BC remain poorly understood. Here, we provide literature review aiming to clarify the role of circRNAs in BC and summarize the latest research. We provide a systematic overview of the biogenesis and biological functions of circRNAs, elaborate on the functional roles of circRNAs in BC, and highlight the value of circRNAs as diagnostic and therapeutic targets in BC.

KEYWORDS
Breast cancer; circular RNAs; carcinogenesis; tumor biomarker; targeted therapy

Introduction
Breast cancer (BC) is the malignant tumor type with the highest incidence among women worldwide and the second leading cause of cancer-related death among women. According to the 2019 statistics from the American Cancer Society, there were 268,600 new cases of BC in women worldwide, accounting for 30% of all new cancer diagnoses in women, and 41,760 deaths, accounting for 15% of cancer deaths among women1,2. Despite the availability of treatments such as surgery3, chemotherapy4, and targeted therapy5, BC has not yet been fully and effectively controlled6,7. BC has a high mortality rate partly attributed to the rates of recurrence and metastasis. In the United States, each year, more than 150,000 women receive a diagnosis of metastatic BC, and nearly 41,000 deaths from BC occur, virtually all of which are due to metastatic disease6,8. The overall 5-year BC survival rate for patients diagnosed between 2009 and 2015 is 98% for stage I and 27% for stage IV1. There is an urgent need to develop new BC therapies and to identify novel diagnostic markers and therapeutic targets for BC.

In recent years, after substantial research on microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) have become a new focus of studies in the field of noncoding RNA. CircRNAs are noncoding RNAs characterized by single-stranded, covalently closed circular transcripts that lack 5’ caps and 3’ poly(A) tails. These features make circRNAs resistant to digestion by ribonucleases, such as RNase R and exonuclease, thus resulting in longer half-lives than those of linear mRNAs9. CircRNAs were first discovered as viroids in RNA viruses by electron microscopy in 197610 and were found to be endogenous RNA splicing products in eukaryotes in 197911. In subsequent decades, circRNAs were considered to be a result of splicing errors, and only the testis-specific circRNA from the sex-determining region Y (SRY) gene was considered to have a potential function12. However, in the 21st century, the development of RNA sequencing (RNA-seq) technologies and bioinformatics led to the discovery that circRNAs are widespread in eukaryotic cells and are involved in the biogenesis and development of various diseases, including nervous system disorders13, cardiovascular disorders14, and...
Cancer Biol Med Vol 19, No 1 January 2022

cancer\textsuperscript{15-18}. For example, the cancer landscape of circRNAs in brain, lung, thyroid, breast, and bladder cancers was determined through an exome capture RNA-seq protocol, which detected and characterized circRNAs across more than 2000 cancer samples\textsuperscript{19}. CircRNAs play critical roles in carcinogenesis, metastasis, and resistance to therapy\textsuperscript{18,20}. The stability and tissue specificity of circRNAs in exosomes or body fluids\textsuperscript{21,22} suggest that circRNAs may serve as reliable tumor biomarkers for diagnosis or prognostication, as well as potential therapeutic targets in various cancers including BC\textsuperscript{23,24}.

A systematic understanding of the functions and mechanisms underlying the roles of circRNAs in BC tumorigenesis and development may contribute to the discovery of novel diagnostic methods and effective therapies. Here, we provide an overview of the biogenesis and biological functions of circRNAs, elaborate on the functional roles of circRNAs in BC, and highlight the value of circRNAs as diagnostic factors and therapeutic targets in BC.

The biogenesis of circRNAs

CircRNAs are formed through pre-mRNA back-splicing, which connects a downstream splice donor site (5′ splice site) to an upstream acceptor splice site (3′ splice site), and transcription by RNA polymerase II (RNA pol II)\textsuperscript{25}. Different circRNAs can be formed from the same sequences through alternative back-splicing. Despite years of intense research efforts, the exact mechanism underlying circRNA formation is not completely understood. According to their composition and cycling mechanisms, circRNAs are divided into 3 groups: exonic circRNAs (ecircRNAs)\textsuperscript{26,27}, exon-intron circRNAs (ElciRNAs)\textsuperscript{28}, and circular intronic RNAs (ciRNAs)\textsuperscript{29}. ecircRNAs are predominantly localized to the cytoplasm, and they contain 1 or multiple exons, with 2 or 3 exons derived from alternative splicing\textsuperscript{27,30}. There are 3 hypothetical models explaining the biogenesis of ecircRNAs: lariat-driven circularization, intron-pairing-driven circularization, and RNA binding protein (RBP)-mediated circularization\textsuperscript{31}. In the generation of ecircRNAs, partial RNA folding occurs during pre-mRNA transcription, and exons are skipped as the RNA is folded. These structural changes result in the formation of specific regions called lariat structures, in which initially non-adjacent exons, along with their introns, become close to each other. CircRNAs are then formed after the intron sequence is removed through splicing within the lariat structure. This model is defined as lariat-driven circularization. Reverse complementary sequences are present in introns on both sides of the pre-mRNA; therefore, the complementary pairing of introns on both sides mediates circRNA generation. This model is defined as intron-pairing-driven circularization. RBPs that function as transacting activators or inhibitors play significant roles in regulating circRNA production. The RNA editing enzyme adenosine deaminase 1 (ADAR1) antagonizes circRNA biogenesis by directly weakening inverted ALU repeats through A-to-I editing of RNA pairing flanking circularized exons, thereby decreasing the complementarity and stability of intron base pairing interactions\textsuperscript{27,32,33}. DHX9, an abundant nuclear RNA helicase, is another ALU element target similar to ADAR1. Loss of DHX9 increases circRNA production through a process mediated by unwinding of RNA pairs flanking circularized exons\textsuperscript{34}. In addition, several splicing factors can bind specific RNA motifs and subsequently regulate circRNA biogenesis. Quaking (QKI), a mesenchymal splicing factor, contributes to the regulation of circRNA production in epithelial-mesenchymal transition (EMT)\textsuperscript{35}. The RNA-binding protein FUS controls back-splicing reactions leading to circRNA production in mouse embryonic stem cell-derived motor neurons\textsuperscript{36}. ElciRNAs are composed of exons and retained introns, and are predominantly localized to the nucleus, where they promote the transcription of parental genes\textsuperscript{28}. In the generation of ecircRNAs, introns that surround the exons are usually spliced out. However, in some cases, introns are retained and subsequently form ElciRNAs\textsuperscript{28}. Although some lariat structures are generated by introns during splicing, most are degraded rapidly through debranching. Only some lariat structures containing essential nucleic acid sequences, such as a 7 nt GU-rich element adjacent to the 5′ splice site and an 11 nt C-rich element adjacent to the branch point site, are not debranched after splicing, thus forming ciRNAs\textsuperscript{29}. The biogenesis of circRNAs is shown in Figure 1. CircRNAs can also be generated from lncRNAs, such as long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT), which have been shown to encode regulatory peptides in glioblastoma, thus revealing the abundance and complexity of RNA sources\textsuperscript{37}.

The function of circRNAs

CircRNAs act as miRNA sponges or competing endogenous RNAs

According to the competing endogenous RNA (ceRNA) hypothesis, miRNAs act as gene expression regulatory elements that affect mRNA stability and translation at the
post-transcriptional level through direct base pairing with target sites; miRNA activity can be affected by miRNA sponge transcripts. CircRNAs that contain various types and numbers of miRNA binding sites can function as ceRNAs or miRNA sponges, thus inhibiting miRNAs and consequently regulating the expression of miRNA-related target gene by MREs. The most widely known circRNA is ciRS-7 (circRNA sponge for miR-7), which contains more than 70 selectively conserved miRNA target sites and is highly associated with Argonaute (AGO) proteins in a miR-7-dependent manner. In human and murine brain tissues, ciRS-7 acts as a molecular sponge for miR-7 and inhibits miRNA function, thus positively regulating miR-7 target genes. Kleaveland et al. have found a regulatory network centered on 4 ncRNAs—the IncRNA Cyrano, the circRNA ciRS-7, and 2 miRNAs, miR-671 and miR-7—in the mammalian brain. Loss of Cyrano increases miR-7 levels, thus causing cytoplasmic destruction of Cdr1as in neurons, partly through enhanced miR-671-directed slicing. CircSry, which is derived from the sex-determining region Y, serves as a miR-138 sponge in the mouse testis, thus providing early evidence that circRNAs can act as molecular sponges. Another well-known circRNA, circHIPK3, acts as a sponge for 9 miRNAs, with 18 potential binding sites in multiple human tissues, including miR-124, miR-7, miR-4288, and miR-558. Circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21 and PTEN expression. Together, these findings suggest that the miRNA sponging effects of circRNAs may be a general phenomenon in cancer.
CircRNAs regulate transcription and splicing

Although numerous studies support the roles of circRNAs as miRNA sponges, ElciRNAs and ciRNAs, which are primarily enriched in the nucleus, had been demonstrated to regulate gene expression in a transcriptional or post-transcriptional manner. ElciRNAs, such as ElciPAIP2 and ElciEIF3J, are predominantly localized to the nucleus, where they interact with U1 small nuclear ribonucleoproteins and RNA pol II, and promote the transcription of parental genes. Linear splicing and circRNA formation mutually regulate each other through competition for splice sites, in a manner that is tissue specific and conserved in animals.

CircRNAs bind proteins

Certain circRNAs interact with different proteins and form circRNA-protein complexes that regulate the subcellular localization of proteins, the activity of associated proteins, and the transcription of parental or related genes. Du et al. have demonstrated that circ-Foxo3 interacts with the senescence-related proteins ID1 and E2F1, and the stress-related proteins HIF1α and FAK, thus increasing cellular senescence through the suppression of anti-senescent and anti-stress roles. Another study has shown that the circ-Foxo3 interacts with the cell cycle proteins cyclin-dependent kinase 2 (CDK2) and cyclin-dependent kinase inhibitor 1 (p21), thereby hindering cell cycle progression via the formation of the circ-Foxo3-p21-CDK2 ternary complex. In addition, circ-Foxo3 binds both p53 and MDM2 and subsequently promotes MDM2-induced p53 ubiquitination and represses MDM2-induced Foxo3 ubiquitination, thereby inducing cell apoptosis. Abdelmohsen et al. have proposed that the extensive binding of circPABPN1 to HuR prevents HuR binding to PABPN1 mRNA and suppresses PABPN1 translation, thus providing an example of competition between a circRNA and its cognate mRNA for an RBP that affects translation. In another example, circACC1 affects cellular responses to metabolic stress and promotes the enzymatic activity of the AMPK holoenzyme by forming a ternary complex with the regulatory β and γ subunits.

CircRNAs can be translated

Early studies have reported that circRNAs, as non-coding RNAs, cannot be translated via cap-dependent mechanisms because of their lack of a 5′ cap and 3′ poly(A) tail. However, increasing recent evidence indicates that circRNAs encode proteins. A circRNA database called circRNADb lists 16,328 circRNAs containing an open reading frame (ORF) longer than 100 amino acids, of which 7,170 have internal ribosome entry site (IRES) elements. In addition, 46 circRNAs from 37 genes express proteins, according to mass spectrometry. Circ-ZNF609, which contains an ORF, can be translated into a protein in a splicing-dependent and cap-independent manner, thus providing an example of a protein-coding circRNA in eukaryotes. Yang et al. have proposed that the spanning junction ORF in circ-FBXW7 driven by IRES encodes a novel 21-kDa protein, termed FBXW7-185aa, which decreases the half-life of c-Myc by antagonizing USP28-induced c-Myc stabilization, and inhibits proliferation and progression in glioblastoma. Another example is circ-SHPRH, which uses overlapping genetic codes to generate a UGA stop codon, thereby resulting in the translation of the 17 kDa SHPRH-146aa. CircFBXW7, which acts as a sponge for miR-197-3p, encodes the FBXW7-185aa protein, which suppresses triple-negative breast cancer (TNBC) progression by upregulating FBXW7 expression. Zhang et al. have identified a peptide encoded by the circular LINC-PINT, which directly interacts with polymerase associated factor complex (PAF1c) and inhibits the transcriptional elongation of multiple oncogenes.

In addition to the IRESs and ORFs responsible for circRNA translation, N6-methyladenosine (m6A), the most abundant base modification of RNA, efficiently promotes protein translation from circRNAs in human cells. m6A-driven translation requires the initiation factor eIF4G2 and the m6A reader YTHDF3; it is enhanced by the methyltransferases METTL3/14, inhibited by the demethylase FTO, and upregulated by heat shock. Although the translation of circRNAs has recently been identified, additional coding circRNAs and the mechanisms underlying their translation remain elusive.

The study of circRNAs in BC

The development of high-throughput sequencing and circRNA microarrays has led to the identification of an increasing number of circRNAs with potential value in BC diagnosis, treatment, and prognostication. The functions and clinical applications of circRNAs in BC are described below.
Expression of circRNAs in BC

Dysregulated expression of circRNAs in BC tissues compared with adjacent normal tissues has oncogenic or tumor-suppressive roles in the initiation and progression of BC. A study has identified 1,155 circRNAs including 715 upregulated and 440 downregulated circRNAs, that are aberrantly expressed in BC tissues compared with adjacent normal-appearing tissues\(^5\). Tang et al.\(^5\) have shown through circRNA microarray analysis that 1,705 circRNAs are aberrant in BC tissue. Yin et al.\(^5\) have detected 19 upregulated circRNAs and 22 downregulated circRNAs in plasma specimens from patients with BC. The number reported above may not represent the actual number of altered circRNAs in BC, and further studies are needed to identify additional dysregulated circRNAs. Table 1 lists the dysregulated circRNAs in BC reported in the PubMed database.

CircRNAs affect the proliferation and progression of BC through a ceRNA mechanism

Increasing evidence supports the association between the circRNA-miRNA-mRNA network and tumorigenesis. CircRNAs function as miRNAs sponges that regulate the proliferation, metastasis, and invasion of cancers, including BC. For example, circKIF4A, which is associated with poorer outcomes in TNBC, exerts its regulatory functions in TNBC through regulating the expression of KIF4A by sponging miR-375\(^8\). The activity of circSEPT9, mediated by E2F1 and ELF4A3, promotes carcinogenesis and TNBC development through the circSEPT9/miR-637/LIF axis\(^11\). Liang et al.\(^11\) have demonstrated that circCDYL promotes autophagy by sponging miR-1275 and upregulates the expression of the autophagy-associated gene ATG7 and ULK1. CircHMCU is upregulated in human BC and promotes the proliferation, migration, and invasion of BC cells by affecting the G1 phase cell cycle checkpoint and the EMT pathway. In addition, circHMCU binds miRNA let-7 family members, thus increasing the expression of the let-7 family target genes such as MYC, HMGA2, and CCND1\(^11\). Certain circRNAs, such as circIRAK3\(^6\), circANKS1B\(^6\), and ciRS-7\(^7\), promote BC cell migration, invasion, and metastasis, but have no effect on the proliferation and growth of BC. CircIRAK3 is upregulated in metastatic BC cells and exerts regulatory roles in BC metastasis via the circIRAK3/miR-3607/FOXC1 signaling axis\(^6\). Zeng et al.\(^6\) have characterized a novel circRNA, circANKS1B, that is upregulated in TNBC and promotes BC invasion and metastasis by inducing EMT. Mechanistically, circANKS1B sponges miR-148a-3p and miR-152-3p, thereby upregulating expression of the transcription factor USF1, which in turn upregulates TGF-β1 expression, activates TGF-β1/Smad signaling, and promotes EMT. Together, these findings suggest that circRNA-miRNA-mRNA interaction networks play vital roles in BC proliferation and progression.

CircRNAs affect the proliferation and progression of BC through cancer-associated signaling pathways

Multiple cancer-associated signaling pathways are involved in the proliferation and progression of BC. In addition to the ceRNA mechanism, substantial evidence indicates that circRNAs play key roles in the proliferation, migration, invasion, and metastasis of BC by regulating the expression of target genes directly or by interacting with mRNAs or proteins associated with cancer-related signaling pathways. Mutant p53 suppresses cancer progression and malignancy\(^15\). Circ-Ccnb1, which is downregulated in BC, binds H2AX and wild-type p53, thus preventing the induction of cell death; however, in p53 mutant
cells, circ-Ccnb1 forms a complex with H2AX and Bclaf1 and induces cancer cell death and inhibition of tumor progression\textsuperscript{151}. Du et al.\textsuperscript{72} have shown that ectopically expressed circ-Dnmt1 interacts with both p53 and AUF1, and promotes the nuclear translocation of both proteins, thereby increasing the proliferation and survival of BC cells through stimulating cellular autophagy. The nuclear translocation of p53 induces cellular autophagy, whereas the nuclear translocation of AUF1 increases Dnmt1 mRNA stability and translation, thus inhibiting p53 transcription and promoting autophagy. Chen et al.\textsuperscript{74} have identified a novel FLI1 circRNA called FECR1, which regulates metastasis of BC cells by coordinating the DNA methylation and demethylation of target genes involved in tumor growth. FECR1 not only interacts with the FLI1 promoter in cis and recruits TET1 demethylase, but also binds the Dnmt1 promoter and downregulates Dnmt1 in trans. Wu et al.\textsuperscript{134} have presented evidence that circYap binds Yap mRNA and the translation initiation associated proteins eIF4G and PABP, thus suppressing Yap translation initiation and delaying tumor progression. CircSKA3 promotes tumor progression by
| Name                  | Expression | Function                  | Mechanism                           | Reference |
|-----------------------|------------|---------------------------|-------------------------------------|-----------|
| circ-ABC10            | Up         | Oncogene                  | miR-1271                            | 60        |
| circDENND4C           | Up         | Oncogene                  | HIF1α                               | 61        |
| circGFRA1             | Up         | Oncogene in TNBC          | miR-34a/GFRA1                       | 62        |
| hsa_circ_0001982      | Up         | Oncogene                  | miR-143                             | 58        |
| circRNA_BARD1         | Up         | Oncogene                  | miR-3942-3p/BARD1                   | 63        |
| hsa_circ_0011946      | Up         | Oncogene                  | miR-26a/b-RFC3                      | 64        |
| circMYO9B             | Up         | Oncogene                  | miR-4316/FOXP4                      | 65        |
| circIRAK3             | Up         | Metastasis                | miR-3607/FOXC1                      | 66        |
| hsa_circ_0008039      | Up         | Oncogene                  | miR-432-5p/E2F3                     | 67        |
| circANKS1B            | Up         | Metastasis                | miR-148a-3p/152-3p-USF1             | 68        |
| hsa_circ_0007534      | Up         | Oncogene                  | miR-593/MUC19                       | 69        |
| ciRS-7                | Up         | Oncogene in TNBC          | miR-1299/MMPs                       | 70        |
| circRNA-MTO1          | Up         | Monastrol resistance      | TRAF4/Eg5                           | 71        |
| circ-DNMT1            | Up         | Oncogene                  | Activation of autophagy             | 72        |
| circEPST11            | Up         | Oncogene in TNBC          | miR-4753/6809-BCL11A                | 73        |
| FECR1                 | Up         | Metastasis                | TET1 and DNMT1                      | 74        |
| circ-UBAP2            | Up         | Oncogene in TNBC          | miR-661/MTA1                        | 75        |
| circZNF609            | Up         | Oncogene                  | miR-145-5p/p70S6K1                  | 76        |
| hsa_circ_0072995      | Up         | Oncogene                  | miR-30c-2-3p                        | 77        |
| hsa_circ_0052112      | Up         | Oncogene                  | miR-125a-5p                         | 78        |
| hsa_circ_0006528      | Up         | Oncogene and adriamycin resistance | miR-7-5p/MAPK/ERK pathway       | 79        |
| hsa_circ_001569       | Up         | Oncogene                  | PI3K-AKT pathway                    | 80        |
| circAGFG1             | Up         | Oncogene in TNBC          | miR-195-5p/CCNE1                    | 81        |
| hsa_circ_001783       | Up         | Oncogene                  | miR-200c-3p                         | 82        |
| circKIF4A             | Up         | Oncogene in TNBC          | miR-375/KIF4A                       | 83        |
| CDR1as                | Up         | 5-fluorouracil resistance | miR-7/CCNE1                         | 84        |
| circ_0103552          | Up         | Oncogene                  | miR-1236                            | 85        |
| hsa_circ_0136666      | Up         | Oncogene                  | miR-1299/CDK6                       | 86        |
| circRNA-CER           | Up         | Oncogene                  | miR-136/MMP13                       | 87        |
| hsa_circ_0004771      | Up         | Oncogene                  | miR-653/ZEB2                        | 88        |
| circRNA_069718        | Up         | Oncogene in TNBC          | Wnt/β-catenin pathway               | 89        |
| circANKRD12           | Up         | Oncogene                  | Cell cycle                          | 90        |
| circRNA_100876        | Up         | Oncogene                  | miR-361-3p                          | 91        |
| circPLK1              | Up         | Oncogene in TNBC          | miR-296-5p/PLK1                     | 92        |
| circ-UBE2D2           | Up         | Oncogene                  | miR-1236/1287                       | 93        |
| Name                 | Expression | Function                  | Mechanism                  | Reference |
|----------------------|------------|---------------------------|----------------------------|-----------|
| hsa_circ_21439       | Up         | Metastases                | ceRNA                      | 94        |
| circAMOTL1           | Up         | PTX resistance            | AKT pathway                | 95        |
| circDENND4C          | Up         | Oncogene                  | miR-200b/200c              | 96        |
| circ_0067934         | Up         | Oncogene                  | Mcl-1                      | 97        |
| circ-TFCP2L1         | Up         | Oncogene in TNBC          | miR-7/PAK1                 | 98        |
| circFBXL5            | Up         | Oncogene                  | miR-660/SRSF6              | 99        |
| circ_0001667         | Up         | Oncogene                  | miR-125a-5p/TAZ            | 100       |
| circACAP2            | Up         | Oncogene                  | miR-29a/b-3p-COL5A1        | 101       |
| circVAPA             | Up         | Metastases                | miR-130a-5p                | 102       |
| hsa_circ_002178      | Up         | Oncogene                  | miR-328-3p/COL1A1          | 103       |
| circ-TFF1            | Up         | Oncogene                  | miR-326/TFF1               | 104       |
| circ_0007255         | Up         | Oncogene                  | miR-353-5p/SX2             | 105       |
| hsa_circ_0008039     | Up         | Oncogene                  | miR-515-5p/CBX4            | 106       |
| circRNF20            | Up         | Oncogene                  | miR-487a/HIF-1α/HK2        | 107       |
| hsa_circ_0091074     | Up         | Oncogene in TNBC          | miR-1297/TAZ/TEAD4         | 108       |
| circSKA3             | Up         | Oncogene                  | Complex with Tks5 and integrin β1 | 109   |
| circCDYL             | Up         | Oncogene                  | miR-1275-ATG7/ULK1         | 110       |
| circ_103809          | Up         | Oncogene                  | PI3K/AKT                   | 111       |
| circABCB10           | Up         | Oncogene and PTX resistance | let-7a-5p/DUSP7           | 112       |
| circABCB10           | Up         | Oncogene and radioresistance | miR-223-3p/PFN2          | 113       |
| circGNB1             | Up         | Oncogene in TNBC          | miR-141-5p/IGF1R           | 114       |
| circSEPT9            | Up         | Oncogene in TNBC          | miR-637/LIF                | 115       |
| circHMCU             | Up         | Oncogene                  | let-7 family               | 116       |
| circKIF4A            | Up         | Oncogene                  | miR-152/ZEB1               | 117       |
| circRAD18            | Up         | Oncogene                  | miR-613/HK2                | 118       |
| circRAD18            | Up         | Oncogene in TNBC          | miR-208a/3164-IGF1/FGF2    | 119       |
| circ-RNF111          | Up         | PTX resistance            | miR-140-5p/E2F3            | 120       |
| hsa_circ_0000515     | Up         | Oncogene                  | miRNA-296-5p/CXCL10        | 121       |
| hsa_circ_0131242     | Up         | Oncogene in TNBC          | hsa-miR-2682               | 122       |
| circIF30             | Up         | Oncogene in TNBC          | miR-520b-3p/CD44           | 123       |
| circ_DCAF6           | Up         | Oncogene                  | miR-616-3p/GLI1/hedgehog pathway | 124   |
| circEIF3M            | Up         | Oncogene in TNBC          | miR-33a/cyclin D1          | 125       |
| circ-ZEB1            | Up         | Oncogene in TNBC          | miR-448/eEF2 K             | 126       |
| hsa_circRPPH1_015    | Up         | Oncogene                  | miRNA-326/ELK1             | 127       |
forming a complex with Tks5 and integrin β1, thereby inducing invadopodium formation\cite{109}. CircRNA_069718 promotes TNBC progression by activating the Wnt/β-catenin pathway\cite{89}. Hsa_circ_0072309 and hsa_circ_103809 promote BC progression by regulating the PI3K/AKT signaling pathway\cite{80,111}. Despite extensive research, many of the cancer-associated signaling pathways mediating the regulatory functions of circRNAs in BC progression remain unknown. The identification of other circRNAs involved in cancer-associated signaling pathways may improve understanding of the molecular mechanisms underlying BC.

**CircRNAs function as potential novel biomarkers for BC diagnosis and prognostication**

The limitations of mammography, breast ultrasound, and histopathology in the early diagnosis of BC underscore the need to identify novel biomarkers for early BC detection and prognostication. The main characteristics of circRNAs are their abundance, stability, conservatism, location, and specificity. Because of these features, circRNAs show promise as potential noninvasive biomarkers for diagnosis and

| Name                | Expression | Function               | Mechanism                                      | Reference |
|---------------------|------------|------------------------|------------------------------------------------|-----------|
| circMMP11           | Up         | Oncogene               | miR-1204/MMP11                                 | 128       |
| circ-Foxo3          | Down       | TS                     | p53 and MDM2                                   | 49        |
| circRNA-000911      | Down       | TS                     | miR-449a                                       | 129       |
| circ-Ccnb1          | Down       | TS                     | p53 mutation                                   | 130       |
| circ-ITCH           | Down       | TS in TNBC             | miR-214/17-Wnt/β-catenin pathway                | 131       |
| circASS1            | Down       | Inhibition of metastasis| miR-4443/ASS1                                   | 132       |
| hsa_circ_0072309    | Down       | TS                     | miR-492                                        | 133       |
| circYap             | Down       | TS                     | Suppression of translation                      | 134       |
| circTADA2As         | Down       | TS in TNBC             | miR-203a-3p/SOCS3                               | 135       |
| circRNA_0025202     | Down       | TS and tamoxifen resistance | miR-182-5p/FOXO3a                             | 136       |
| circBMPR2           | Down       | TS and tamoxifen resistance | miR-553/USP4                                   | 137       |
| circFBXW7           | Down       | TS in TNBC             | miR-197-3p/FBXW7, and encoded 185-aa protein   | 138       |
| circKDM4C           | Down       | TS and doxorubicin resistance | miR-548p/PBLD                                 | 139       |
| circAHNAK1          | Down       | TS in TNBC             | miR-421/RASA1                                   | 140       |
| hsa_circ_0000376    | Down       | TS                     | miR-1285-3p/SMURF1-BTRC-TP53                    | 141       |
| hsa_circ_0068033    | Down       | TS                     | miR-659                                        | 142       |
| circ-LARP4          | Down       | Doxorubicin resistance  | /                                               | 143       |
| circSCYL2           | Down       | Inhibition of metastasis| EMT                                             | 144       |
| circEHMT1           | Down       | TS                     | miR-1233-3p/KLF4/MMP2                          | 145       |
| circNFIC            | Down       | TS                     | miR-658/UPK1A                                   | 146       |
| circRNA_103809      | Down       | TS                     | miR-532-3p                                     | 147       |
| circ-1073           | Down       | TS                     | Interaction with HuR                            | 148       |
| circDDX17           | Down       | TS                     | miR-605/CDK1 and p21                           | 149       |

**Table 1** Continued

TS, tumor suppressor; Up, upregulation; Down, downregulation; TNBC, triple-negative breast cancer.
CircRNAs can be detected in body fluids (such as blood, plasma, serum, and exosomes) from patients with BC and are associated with clinicopathological characteristics, survival time, and prognosis. Wang et al. have identified 1,147 and 1,195 circRNAs that are dysregulated in exosomes from patients with metastatic and localized BC, respectively. CircCNOT2 is detectable in cell-free plasma RNA and is a predictor of progression-free survival time in patients with advanced breast cancer receiving aromatase inhibitor therapy. Li et al. have shown that hsa_circ_0069094, hsa_circ_0079876, hsa_circ_0017650, and hsa_circ_0017526 are upregulated in the plasma of patients with BC and are significantly associated with tumor volume, TNM stage, and lymph node infiltration. Patients with BC with higher circCDYL levels in the serum or tumor tissues have a higher tumor burden, shorter survival, and poorer clinical response to therapy. These examples are only a fraction of the instances in which circRNAs have been shown to have diagnostic and prognostic potential in BC. Therefore, the clinical application of circRNAs as biomarkers for diagnosis and prognostication must be further studied in the future.

**CircRNAs function as potential novel therapeutic targets in BC**

Many circRNAs are involved in the growth, progression, and drug resistance of BC, thus suggesting that circRNAs have great potential as novel therapeutic targets. Some circRNAs are upregulated in BC tissues and function as oncogenes through a ceRNA mechanism or cancer-associated signal pathways. Many circRNAs have various binding sites for specific miRNAs, and are thus effective miRNA inhibitors through the circRNA-miRNA-mRNA network. Advances in technologies such as siRNA-based therapy, anti-sense oligonucleotide therapy, and the CRISPR/Cas system, among others, may enable the downregulation or suppression of oncogenic circRNAs in the future. In addition, epigenetic modifications of RNA, including m6A, play significant roles in regulating the biogenesis and metabolism of circRNAs. A recent study has found that a subset of m6A-containing circRNAs interacts with YTHDF2 in an HRSP12-dependent manner and is selectively downregulated by the RNase P/MRP, thus representing a potential novel way to degrade oncogenic circRNAs. The study has also indicated that the permuted intron-exon method may be a promising method for development of new drugs associated with circRNAs.

Recent studies have shown that some circRNAs are downregulated in BC tissues and function as tumor suppressors. CircTADA2As has been found to be significantly decreased in a large cohort of patients with BC, and to suppress BC progression and metastasis by targeting the miR-203a-3p/SOCS3 axis. The downregulation of circTADA2As is associated with poor patient survival in TNBC. Ye et al. have demonstrated that circFBXW7 sponges miR-197-3p and encodes the FBXW7-185aa protein, thus suppressing TNBC progression by upregulating FBXW7 expression. Circ-1073 functions as a tumor suppressor in BC. Injection of nanoparticles containing a plasmid encoding circ-1073 has been shown to inhibit the growth of xenograft tumors; consequently, circRNAs in the plasma may contribute to the suppression of BC in vivo. Lin et al. have recently developed a TV-circRGPD6 nanoparticle that selectively expresses circRGPD6 in metastatic breast cancer stem cells and eradicates BC metastasis. These findings indicate that the development of nanotechnology, including synthetic tumor inhibitors, may lead to the application of circRNAs in BC treatment.

Chemotherapy is an effective strategy for the clinical treatment of BC, and chemoresistance is a major cause of treatment failure and poor prognosis in patients with BC. Therefore, clarifying the molecular pathways associated with chemoresistance, increasing the chemosensitivity of cancer cells, and predicting the efficacy of chemotherapeutic agents in individual patients are vital for the clinical management of BC. CircRNAs are involved in the pathogenesis of BC associated with chemotherapy resistance. Gao et al. have found that circ_0006528 is upregulated in adriamycin-resistant BC cells and tissues and plays a role in BC chemoresistance via the circ_0006528-miR-7–5p-Raf1 axis. The circRNA CDR1as decreases the chemosensitivity of 5-fluorouracil resistant BC cells by inhibiting miR-7, thus regulating CCNE1. Hsa_circ_0025202, which is downregulated in BC, functions as a miR-182-5p sponge and relieves the suppression of FOXO3a, thereby increasing cell apoptosis and sensitivity to tamoxifen. Liang et al. have demonstrated that circBMPR2 inhibits the progression and tamoxifen resistance of BC via the circBMPR2/miR-553/USP4 axis. CircBMPR2 knockdown promotes tamoxifen resistance in BC cells by inhibiting tamoxifen-induced apoptosis, whereas circBMPR2 overexpression decreases tamoxifen resistance. CircKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating the miR-548p/PBLD axis in BC. Paclitaxel (PTX) has been approved for use alone or in combination with other drugs against BC.
Cells overexpressing circAMOTL1 show increased resistance to PTX, but not epirubicin and cyclophosphamide, in BC. Mechanically, circAMOTL1 suppresses cell apoptosis and promotes cell survival by activating AKT, and phosphorylated AKT upregulates the anti-apoptotic gene BCL2 and inhibits the proapoptotic genes BAX and BAK. Circ-ABCB10 depletion promotes PTX sensitivity and apoptosis, and suppresses the invasion and autophagy of PTX-resistant BC cells via the let-7a-5p/DUSP7 axis. Circ-RNF111, which is upregulated in PTX-resistant BC tissues, decreases PTX resistance in BC by upregulating E2F3 via sponging miR-140-5p. The roles of circRNAs in chemotherapy resistance and the clinical application of circRNAs to overcome chemotherapy resistance require further exploration.

Conclusions

Extensive studies have confirmed that circRNAs play key roles in the initiation and progression of BC, thus suggesting their potential as novel diagnostic biomarkers and effective therapeutic targets. However, the mechanisms underlying the association between circRNAs and BC remain elusive, and the clinical application of circRNAs has consequently been limited. Elucidation of the molecular mechanisms underlying the role of circRNAs in BC is necessary.

Grant support

This work was supported by funds from the National Natural Science Foundation of China (Grant No. 81772961).

Conflict of interest statement

No potential conflicts of interest are disclosed.

References

1. DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019; 69: 438-51.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69: 7-34.
3. Tosello G, Torloni MR, Mota BS, Neeman T, Riera R. Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev. 2018; 3: Cd011276.
4. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976; 294: 405-10.
5. Liu M, Li Z, Yang J, Jiang Y, Chen Z, Ali Z, et al. Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment. Cell Prolif. 2016; 49: 409-20.
6. Waks AG, Winer EP. Breast cancer treatment: a review. J Am Med Assoc. 2019; 321: 288-300.
7. Woolston C. Breast cancer. Nature. 2015; 527: S101.
8. Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017; 26: 809-15.
9. Harland R, Misher L. Stability of RNA in developing Xenopus embryos and identification of a destabilizing sequence in TFIIIA messenger RNA. Development. 1988; 102: 837-52.
10. Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A. 1976; 73: 3852-6.
11. Hsu MT, Coca-Prados M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature. 1979; 280: 339-40.
12. Capel B, Swain A, Nicolis S, Hacker A, Walter M, Koopman P, et al. Circular transcripts of the testis-determining gene Sry in adult mouse testis. Cell. 1993; 73: 1019-30.
13. Bai Y, Zhang Y, Han B, Yang L, Chen X, Huang R, et al. Circular RNA DLGAP4 ameliorates ischemic stroke outcomes by targeting miR-143 to regulate Endothelial-Mesenchymal Transition associated with blood-brain barrier integrity. J Neurosci. 2018; 38: 32-50.
14. Holdt LM, Stahringer A, Sass K, Pichler G, Kulak NA, Wilfert W, et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. Nat Commun. 2016; 7: 12429.
15. Kristensen LS, Andersen MS, Stagsted LJV, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 2019; 20: 673-91.
16. Li S, Han L. Circular RNAs as promising biomarkers in cancer: detection, function, and beyond. Genome Med. 2019; 11: 15.
17. Shang Q, Yang Z, Jia R, Ge S. The novel roles of circRNAs in human cancer. Mol Cancer. 2019; 18: 6.
18. Su M, Xiao Y, Ma J, Tang Y, Tian B, Zhang Y, et al. Circular RNAs in Cancer: emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers. Mol Cancer. 2019; 18: 90.
19. Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, et al. The landscape of circular RNA in cancer. Cell. 2019; 176: 869-81.e13.
20. Guarnerio J, Bezzi M, Jeong JC, Paffenholz SV, Berry K, Naldini MM, et al. Oncogenic role of fusion-circRNAs derived from cancer-associated chromosomal translocations. Cell. 2016; 166: 1055-6.
21. Wang Y, Liu J, Ma J, Sun T, Zhou Q, Wang W, et al. Exosomal circRNAs: biogenesis, effect and application in human diseases. Mol Cancer. 2019; 18: 116.
22. Bahn JH, Zhang Q, Li F, Chan TM, Lin X, Kim Y, et al. The landscape of microRNA, Piwi-interacting RNA, and circular RNA in human saliva. Clin Chem. 2015; 61: 221-30.

23. Li Z, Chen Z, Hu G, Jiang Y. Roles of circular RNA in breast cancer: present and future. Am J Transl Res. 2019; 11: 3945-54.

24. Wang X, Fang L. Advances in circular RNAs and their roles in breast cancer. J Exp Clin Cancer Res. 2018; 37: 206.

25. Ashwal-Fluss R, Meyer M, Pamudurti NR, Ivanov A, Bartok O, Hanan M, et al. circRNA biogenesis competes with pre-mRNA splicing. Mol Cell. 2014; 56: 55-66.

26. Chen I, Chen CY, Chuang TJ. Biogenesis, identification, and function of exonic circular RNAs. Wiley Interdiscip Rev RNA. 2015; 6: 563-79.

27. Zhang XQ, Wang HB, Zhang Y, Lu X, Chen LL, Yang L. Complementary sequence-mediated exon circularization. Cell. 2014; 159: 134-47.

28. Li Z, Huang C, Bao C, Chen L, Lin W, Yang X, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015; 22: 256-64.

29. Zhang Y, Zhang XO, Chen T, Xiang JF, Yin QF, Xing YH, et al. Circular intronic long noncoding RNAs. Mol Cell. 2013; 51: 792-806.

30. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013; 495: 333-8.

31. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013; 19: 141-57.

32. Rybak-Wolf A, Stottemeier C, Glazar P, Jens M, Pino N, Giusti S, et al. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol Cell. 2015; 58: 870-85.

33. Ivanov A, Memczak S, Wyler E, Torti F, Porath HT, Orejuela MR, et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 2015; 10: 170-7.

34. Aktaş T, Ayvar Işık I, Maticzka D, Bhardwaj V, Pessoa Rodrigues C, Mittler G, et al. DHX9 suppresses RNA processing defects originating from the Alu invasion of the human genome. Nature. 2017; 544: 115-9.

35. Conn SJ, Pillman KA, Toubia J, Conn VM, Salamidis M, Phillips CA, et al. The RNA binding protein quaking regulates formation of circRNAs. Cell. 2015; 160: 1125-34.

36. Errichelli L, Dini Modigliani S, Laneve P, Colantoni A, Legnini I, Capauto D, et al. FUS affects circular RNA expression in murine embryonic stem cell-derived motor neurons. Nat Commun. 2017; 8: 14741.

37. Zhang M, Zhao K, Xu X, Yang Y, Yan S, Wei P, et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat Commun. 2018; 9: 4475.

38. Salmena L, Poliseno L, Tay Y, Cats L, Pandolfi PP. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011; 146: 353-8.

39. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013; 495: 384-8.

40. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014; 505: 344-52.

41. Kleveland B, Shi CY, Stefano J, Bartel DP. A network of noncoding regulatory RNAs acts in the mammalian brain. Cell. 2018; 174: 350-62.e17.

42. Zheng Q, Bao C, Guo W, Li S, Chen J, Chen B, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun. 2016; 7: 11215.

43. Zeng K, Chen X, Xu M, Liu X, Hu X, Xu T, et al. CircHIPK3 promotes colorectal cancer growth and metastasis by sponging miR-7. Cell Death Dis. 2018; 9: 417.

44. Ke Z, Xie F, Zheng C, Chen D. CircHIPK3 promotes proliferation and invasion in nasopharyngeal carcinoma by abrogating miR-4288-induced ELF3 inhibition. J Cell Physiol. 2019; 234: 1699-706.

45. Li Y, Zheng F, Xiao X, Xie F, Tao D, Huang C, et al. CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. EMBO Rep. 2017; 18: 1646-59.

46. Yang C, Yuan W, Yang X, Li P, Wang J, Han J, et al. Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression. Mol Cancer. 2018; 17: 19.

47. Du WW, Yang W, Chen Y, Wu ZK, Foster FS, Yang Z, et al. Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses. Eur Heart J. 2017; 38: 1402-12.

48. Du WW, Yang W, Liu E, Yang Z, Dhaliwal P, Yang BB. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 2016; 44: 2846-58.

49. Du WW, Fang L, Yang W, Wu N, Awan FM, Yang Z, et al. Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity. Cell Death Differ. 2017; 24: 357-70.

50. Abdelmohsen K, Panda AG, Munk R, Grammatikakis I, Dudekula DB, De S, et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1. RNA Biol. 2017; 14: 361-9.

51. Li Q, Wang Y, Wu S, Zhou Z, Ding X, Shi R, et al. CircACC1 regulates assembly and activation of AMPK complex under metabolic stress. Cell Metab. 2019; 30: 157-73.e7.

52. Chen X, Han P, Zhou T, Guo X, Song X, Li Y. circRNAdb: a comprehensive database for human circular RNAs with protein-coding annotations. Sci Rep. 2016; 6: 34985.

53. Legnini I, Di Tomaso G, Rossi F, Morlando M, Briganti F, Sthandier O, et al. Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. Mol Cell. 2017; 66: 22-37.e9.

54. Yang Y, Gao X, Zhang M, Yan S, Sun C, Xiao F, et al. Novel role of Fox5 circular RNA in repressing glioma tumorigenesis. J Natl Cancer Inst. 2018; 110: 304-15.

55. Zhang M, Huang N, Yang X, Luo J, Yan S, Xiao F, et al. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene. 2018; 37: 1805-14.

56. Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y, et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 2017; 27: 626-41.
Liu Y, Dong Y, Zhao L, Su L, Luo J. Circular RNA-MTO1 suppresses breast cancer cell proliferation and progression through sponging miR-1271. Am J Cancer Res. 2017; 7: 1566-76.

Li G, Liu Z, Tan L, Su AN, Jiang WG, Gong G. HIF1α-associated circDENND4C promotes proliferation of breast cancer cells in hypoxic environment. Anticancer Res. 2017; 37: 4337-43.

He R, Liu P, Xie X, Zhou Y, Liao Q, Xiong W, et al. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. J Exp Clin Cancer Res. 2017; 36: 145.

Zhao J, Zou H, Han C, Ma J, Zhao J, Tang J. Circular RNA BARD1 (Hsa_circ_0001098) overexpression in breast cancer cells with TCDD treatment could promote cell apoptosis via miR-3942/ BARD1 axis. Cell Cycle. 2018; 17: 2731-44.

Zhou J, Zhang WW, Peng F, Sun JY, He ZY, Wu SG. Downregulation of hsa_circ_0011946 suppresses the migration and invasion of the breast cancer cell line MCF-7 by targeting RFC3. Cancer Manag Res. 2018; 10: 335-44.

Wang N, Gu Y, Li L, Wang F, Lv P, Xiong Y, et al. Circular RNA circMYO9B facilitates breast cancer cell proliferation and invasiveness via upregulating FOXP4 expression by sponging miR-4316. Arch Biochem Biophys. 2018; 653: 63-70.

Wu J, Jiang Z, Chen C, Hu Q, Fu Z, Chen J, et al. CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis. Cancer Lett. 2018; 430: 130-92.

Liu Y, Lu C, Zhou Y, Zhang Z, Sun L. Circular RNA hsa_circ_0008039 promotes breast cancer cell proliferation and migration by regulating miR-432-5p/E2F3 axis. Biochem Biophys Res Commun. 2018; 502: 358-63.

Zeng K, He B, Yang BB, Xu T, Chen X, Xu M, et al. Profiles of differentially expressed circRNAs in esophageal and breast cancer. Cancer Manag Res. 2018; 10: 2207-21.

Tang YY, Zhao P, Kou TN, Duan JJ, Zhi R, Yang SY, et al. Circular RNA hsa_circ_0001982 promotes breast cancer cell carcinogenesis through decreasing miR-143. DNA Cell Biol. 2017; 36: 901-8.

Yin WB, Yan MG, Fang X, Guo JJ, Xiong W, Zhang RP. Circulating circular RNA hsa_circ_0001785 acts as a diagnostic biomarker for breast cancer detection. Clin Chim Acta. 2018; 487: 363-8.

Liang HF, Zhang XZ, Liu BG, Jia GT, Li WL. Circular RNA circ-DNMT1 enhances breast cancer progression by regulating the TRAF4/Eg5 axis. Int J Oncol. 2018; 53: 1752-62.

Du WW, Yang W, Li X, Awan FM, Yang Z, Fang L, et al. A circular RNA circ-DNMT1 enhances breast cancer progression by activating autophagy. Oncogene. 2018; 37: 5829-42.

He R, Liu P, Xie X, Zhou Y, Liao Q, Xiong W, et al. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. J Exp Clin Cancer Res. 2017; 36: 145.

Yin WB, Yang MG, Fang X, Guo JJ, Xiong W, Zhang RP. Circular RNA hsa_circ_0001982 promotes breast cancer cell carcinogenesis through decreasing miR-143. DNA Cell Biol. 2017; 36: 901-8.

He R, Liu P, Xie X, Zhou Y, Liao Q, Xiong W, et al. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. J Exp Clin Cancer Res. 2017; 36: 145.

Zhou J, Zou H, Han C, Ma J, Zhao J, Tang J. Circular RNA BARD1 (Hsa_circ_0001098) overexpression in breast cancer cells with TCDD treatment could promote cell apoptosis via miR-3942/ BARD1 axis. Cell Cycle. 2018; 17: 2731-44.

Zhou J, Zhang WW, Peng F, Sun JY, He ZY, Wu SG. Downregulation of hsa_circ_0011946 suppresses the migration and invasion of the breast cancer cell line MCF-7 by targeting RFC3. Cancer Manag Res. 2018; 10: 335-44.
Zhao B, Song X, Guan H. CircACAP2 promotes breast cancer proliferation and metastasis by targeting miR-29a/b-3p-COL5A1 axis. Life Sci. 2020; 244: 117179.

Zhou H, Tang G, Zhao M, Xie L, Xie Y, Zhang Z, et al. circFBXL5 promotes breast cancer progression by sponging miR-660. J Cell Mol Med. 2020; 24: 2189-2191.

Pan G, Mao A, Liu J, Li J, Ding J, Liu W. Circular RNA hsa_circ_0061825 (circ-TFF1) contributes to breast cancer progression through targeting miR-326/TFF1 signalling. Cell Prolif. 2020; 53: e12720.
117. Jin Y, Yang L, Li X, Liu F. Circular RNA KIF4A promotes cell migration, invasion and inhibits apoptosis through miR-152/ZEB1 axis in breast cancer. Diagn Pathol. 2020; 15: 55.

118. Zang H, Li Y, Zhang X, Huang G. Knockdown of circRAD18 mitigates breast cancer progression through the regulation of miR-613/HK2 axis. Cancer Manag Res. 2020; 12: 3661-72.

119. Zou Y, Zheng S, Xiao W, Xie X, Yang A, Gao G, et al. circRAD18 sponges miR-208a/3164 to promote triple-negative breast cancer progression through regulating IGFB1 and FGFR2 expression. Carcinogenesis. 2019; 40: 1469-79.

120. Zang H, Li Y, Zhang X, Huang G. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p. Thorac Cancer. 2020; 11: 1891-903.

121. Cai F, Fu W, Tang L, Tang J, Sun J, Fu G, et al. Hsa_circ_0000515 is a novel circular RNA implicated in the development of breast cancer through its regulation of the microRNA-296-5p/CXCL10 axis. FEBS J. 2021; 288: 861-83.

122. Li Y, Shi P, Zheng T, Ying Z, Jiang D. Circular RNA hsa_circ_0131242 promotes triple-negative breast cancer progression by sponging hsa-miR-2682. Oncotargets Ther. 2020; 13: 4791-8.

123. Xing L, Yang R, Wang X, Zheng X, Yang X, Zhang L, et al. The circRNA circIFIT30 promotes progression of triple-negative breast cancer and correlates with prognosis. Aging (Albany NY). 2020; 12: 10983-1003.

124. Ye G, Pan R, Zhu L, Shi P, Zheng T, Ying Z, Jiang D. Circular RNA hsa_circRPPH1_015 exerts an oncogenic role in breast cancer by regulating miR-1204. Thorac Cancer. 2020; 11: 1921-9.

125. Peng Z, Xu B, Jin F. Circular RNA hsa_circ_0000376 participates in tumorigenesis of breast cancer and correlates with prognosis. Aging (Albany NY). 2020; 12: 10983-1003.

126. Li Y, Shen Z, Yang Y, Aix T, Yang Z, Tang H, et al. CircRNA_103809 inhibits the proliferation and metastasis of breast cancer cells MDA-MB-231 and suppressed invasion and migration. Epigenomics. 2019; 11: 199-213.

127. Zou Y, Zheng S, Xiao W, Xie X, Yang A, Gao G, et al. circRAD18 sponges miR-208a/3164 to promote triple-negative breast cancer progression through regulating IGFB1 and FGFR2 expression. Carcinogenesis. 2019; 40: 1469-79.

128. Zang H, Li Y, Zhang X, Huang G. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p. Thorac Cancer. 2020; 11: 1891-903.

129. Cai F, Fu W, Tang L, Tang J, Sun J, Fu G, et al. Hsa_circ_0000515 is a novel circular RNA implicated in the development of breast cancer through its regulation of the microRNA-296-5p/CXCL10 axis. FEBS J. 2021; 288: 861-83.

130. Li Y, Shen Z, Yang Y, Aix T, Yang Z, Tang H, et al. CircRNA_103809 inhibits the proliferation and metastasis of breast cancer cells MDA-MB-231 and suppressed invasion and migration. Epigenomics. 2019; 11: 199-213.

131. Yang L, Zheng M, Wang H. Circular RNA hsa_circ_0072309 inhibits proliferation and invasion of breast cancer cells via targeting miR-492. Cancer Manag Res. 2019; 11: 1033-41.

132. Wu N, Yuan Z, Du KY, Fang L, Lyu J, Zhang C, et al. Translation of yes-associated protein (YAP) was antagonized by its circular RNA via suppressing the assembly of the translation initiation machinery. Cell Death Differ. 2019; 26: 2758-73.

133. Xu JZ, Shao CC, Wang XJ, Zhao X, Chen JQ, Ouyang YX, et al. circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis. Cell Death Dis. 2019; 10: 175.

134. Fang L, Du WW, Awan FM, Dong J, Yang BB. The circular RNA Wnt/β-catenin pathway. Neoplasma. 2019; 66: 232-9.

135. Zou Y, Zheng S, Xiao W, Xie X, Yang A, Gao G, et al. circRAD18 sponges miR-208a/3164 to promote triple-negative breast cancer progression through regulating IGFB1 and FGFR2 expression. Carcinogenesis. 2019; 40: 1469-79.

136. Zang H, Li Y, Zhang X, Huang G. Circ-RNF111 contributes to paclitaxel resistance in breast cancer by elevating E2F3 expression via miR-140-5p. Thorac Cancer. 2020; 11: 1891-903.

137. Li Y, Shen Z, Yang Y, Aix T, Yang Z, Tang H, et al. CircRNA_103809 inhibits the proliferation and metastasis of breast cancer cells MDA-MB-231 and suppressed invasion and migration. Epigenomics. 2019; 11: 199-213.
sponging microRNA-532-3p (miR-532-3p). Front Genet. 2020; 11: 485.

148. Yi Z, Li Y, Wu Y, Zeng B, Li H, Ren G, et al. Circular RNA 0001073 attenuates malignant biological behaviours in breast cancer cell and is delivered by nanoparticles to inhibit mice tumour growth. Onco Targets Ther. 2020; 13: 6157-69.

149. Peng HH, Wen YG. CircDDX17 acts as a competing endogenous RNA for miR-605 in breast cancer progression. Eur Rev Med Pharmacol Sci. 2020; 24: 6794-801.

150. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009; 9: 701-13.

151. Fang L, Du WW, Lyu J, Dong J, Zhang C, Yang W, et al. Enhanced breast cancer progression by mutant p53 is inhibited by the circular RNA circ-Ccnb1. Cell Death Differ. 2018; 25: 2195-208.

152. Wang F, Nazarali AJ, Ji S. Circular RNAs as potential biomarkers for cancer diagnosis and therapy. Am J Cancer Res. 2016; 6: 1167-76.

153. Wang J, Zhang Q, Zhou S, Xu H, Wang D, Feng J, et al. Circular RNA expression in exosomes derived from breast cancer cells and patients. Epigenomics. 2019; 11: 411-21.

154. Smid M, Wilting SM, Uhr K, Rodríguez-González FG, de Weerd V, Prager-Van der Smissen WJC, et al. The circular RNAome of primary breast cancer. Genome Res. 2019; 29: 356-66.

155. Li Z, Chen Z, Hu G, Zhang Y, Feng Y, Jiang Y, et al. Profiling and integrated analysis of differentially expressed circRNAs as novel biomarkers for breast cancer. J Cell Physiol. 2020; 235: 7945-59.

156. Wang T, Shigdar S, Shamaileh HA, Gantier MP, Yin W, Xiang D, et al. Challenges and opportunities for siRNA-based cancer treatment. Cancer Lett. 2017; 387: 77-83.

157. Frazier KS. Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist’s perspective. Toxicol Pathol. 2015; 43: 78-89.

158. Zhang Y, Xue W, Li X, Zhang J, Chen S, Zhang JL, et al. The biogenesis of nascent circular RNAs. Cell Rep. 2016; 15: 611-24.

159. Park OH, Ha H, Lee Y, Boo SH, Kwon DH, Song HK, et al. Endoribonucleolytic cleavage of m(6)A-containing RNAs by RNase P/MRP complex. Mol Cell. 2019; 74: 494-507.e8.

160. Puttaraju M, Been MD. Group I permuted intron-exon (PIE) sequences self-splice to produce circular exons. Nucleic Acids Res. 1992; 20: 5357-64.

161. Lin X, Chen W, Wei F, Xie X. TV-circRGPD6 nanoparticle suppresses breast cancer stem cell-mediated metastasis via the miR-26b/YAF2 Axis. Mol Ther. 2021; 29: 244-62.

162. Gao D, Zhang X, Liu B, Meng D, Fang K, Guo Z, et al. Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics. 2017; 9: 1175-88.

163. Russo GL. Toward a personalized use of paclitaxel. Recent Pat Anticancer Drug Discov. 2019; 14: 296-7.

Cite this article as: Zeng Y, Zou Y, Gao G, Zheng S, Wu S, Xie X, et al. The biogenesis, function and clinical significance of circular RNAs in breast cancer. Cancer Biol Med. 2022; 19: 14-29. doi: 10.20892/j.issn.2095-3941.2020.0485